Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

RItuximab From the FIRst Episode of Idiopathic Nephrotic Syndrome

Phase 2

Conditions: Minimal Change Nephrotic Syndrome (MCNS)

Interventions: Drug: Rituximab
Drug: Prednisone

First Posted Date: 2019-05-31

Last Posted Date: 2021-07-13

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 148

Registration Number: NCT03970577

Locations: 🇫🇷
AUDARD, Créteil, France

A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis

First Posted Date: 2019-05-16

Last Posted Date: 2024-11-27

Lead Sponsor: National Human Genome Research Institute (NHGRI)

Target Recruit Count: 45

Registration Number: NCT03952637

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma

Phase 3

Conditions: Peripheral T-cell Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: pegylated liposomal doxorubicin
Drug: Vincristine
Drug: Prednisone
Drug: Doxorubicin

First Posted Date: 2019-05-16

Last Posted Date: 2019-05-16

Lead Sponsor: Peking University

Target Recruit Count: 244

Registration Number: NCT03952572

Locations: 🇨🇳
Peking University Cancer Hospital & Institute, Beijing, Beijing, China

Split-Dose R-CHOP for Older Adults With DLBCL

Phase 2

Active, not recruiting

Conditions: Diffuse Large B Cell Lymphoma
DLBCL
Cancer

Interventions: Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone
Biological: Pegfilgrastim

First Posted Date: 2019-05-09

Last Posted Date: 2024-12-04

Lead Sponsor: University of Wisconsin, Madison

Target Recruit Count: 26

Registration Number: NCT03943901

Locations: 🇺🇸
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States

CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone

Phase 2

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: Cabazitaxel
Drug: Carboplatin
Drug: Abiraterone
Drug: Prednisone

First Posted Date: 2019-05-02

Last Posted Date: 2024-02-28

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 22

Registration Number: NCT03934840

Locations: 🇺🇸
Thomas Jeferson University, Philadelphia, Pennsylvania, United States
🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States

and more 5 locations

Study of Subretinally Injected ATSN-101 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D

Phase 1

Active, not recruiting

Conditions: LCA
LCA1
Leber Congenital Amaurosis

Interventions: Drug: ATSN-101
Drug: ATSN-101 Diluent Solution
Drug: Prednisone
Drug: Triamcinalone Acetonide
Drug: 1% Prednisolone
Drug: Trimethoprim/polymyxin B

First Posted Date: 2019-04-18

Last Posted Date: 2024-02-20

Lead Sponsor: Atsena Therapeutics Inc.

Target Recruit Count: 15

Registration Number: NCT03920007

Locations: 🇺🇸
Casey Eye Institute - Oregon Health & Science University, Portland, Oregon, United States
🇺🇸
Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania, United States

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

Phase 3

Active, not recruiting

Conditions: B Acute Lymphoblastic Leukemia
B Lymphoblastic Lymphoma
Down Syndrome

Interventions: Drug: Asparaginase Erwinia chrysanthemi
Drug: Cyclophosphamide
Biological: Blinatumomab
Drug: Cytarabine
Drug: Dexamethasone
Drug: Doxorubicin Hydrochloride
Drug: Leucovorin Calcium
Drug: Mercaptopurine
Drug: Mercaptopurine Oral Suspension
Drug: Methotrexate
Drug: Pegaspargase
Radiation: Radiation Therapy
Drug: Prednisone
Drug: Prednisolone
Drug: Thioguanine
Drug: Vincristine Sulfate

First Posted Date: 2019-04-16

Last Posted Date: 2024-12-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 6720

Registration Number: NCT03914625

Locations: 🇨🇦
IWK Health Centre, Halifax, Nova Scotia, Canada
🇨🇦
McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇺🇸
Henry Ford Health Saint John Hospital, Detroit, Michigan, United States

and more 225 locations